|

|

Area Editoriale


26/09/2006

Profilassi e terapia dell’osteoporosi nelle IBD

Prevention and Treatment ofOsteoporosis in Inflammatory Bowel Disease.Lichtenstein GR, Sands BE,Pazianas M. Inflamm Bowel Dis. 2006Aug;12(8):797-813.

26/09/2006

Profilassi e terapia dell’osteoporosi nelle IBD

Prevention and Treatment ofOsteoporosis in Inflammatory Bowel Disease.Lichtenstein GR, Sands BE,Pazianas M. Inflamm Bowel Dis. 2006Aug;12(8):797-813.

19/09/2006

Fontolizumab efficace e sicuro nel trattamento del M.di Crohn

A dose escalating, placebocontrolled, double blind, single dose and multidose, safety and tolerabilitystudy of fontolizumab, a humanised anti-interferon gamma antibody, in patientswith moderate to severe Crohn's disease.CHAR(13) + CHAR(10)Reinisch W, Hommes DW, Van Assche G,Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M,Cheng M, van Deventer SJ, Rutgeerts P, Pearce T. Gut. 2006 Aug;55(8):1138-44.

13/09/2006

E’ possibile prevedere la storia naturale del Morbo di Crohn ?

Phenotypeat diagnosis predicts recurrence rates in Crohn's disease F L Wolters, M G Russel, J Sijbrandij, TAmbergen, S Odes, L Riis, E Langholz, P Politi, A Qasim, I Koutroubakis, ETsianos, S Vermeire, J Freitas, G van Zeijl, O Hoie, T Bernklev, M Beltrami, DRodriguez, R W Stockbrügger, B Moum on behalf of the European CollaborativeStudy Group on Inflammatory Bowel Disease (EC-IBD)CHAR(13) + CHAR(10)Gut 2006 55: 1124-1130

02/09/2006

Efficacia della terapia steroidea nelle IBD: uno studio di coorte

The efficacy of corticosteroid therapy in inflammatory bowel disease:analysis of a 5-year UKinception cohort. Ho GT,Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J.CHAR(13) + CHAR(10) Aliment Pharmacol Ther. 2006 Jul15;24(2):319-30.

03/07/2006

La videocapsula è la migliore tecnica diagnostica per il Crohn del tenue


27/06/2006

5-ASA associati ad elevati livelli di 6-TG in pz IBD in remissione con AZA/6-MP


20/06/2006

Fattori prognostici e protettivi di cancro nella Colite Ulcerosa

lbenazzato Scrive"Predictive and protective factors associated with colorectal cancer inCHAR(13) + CHAR(10)ulcerative colitis: a case-control study.CHAR(13) + CHAR(10)CHAR(13) + CHAR(10)Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, TremaineCHAR(13) + CHAR(10)WJ, Sandborn WJ.CHAR(13) + CHAR(10)Gastroenterology. 2006 Jun;130(7):1941-9.CHAR(13) + CHAR(10)

18/06/2006

Colite ulcerosa : quale mesalazina?

Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Gibson PR, Fixa B, Pekarkova B, Batovsky M, Radford-Smith G, Tibitanzl J, Gabalec L, Florin TH, Greinwald R. Aliment Pharmacol Ther. 2006 Apr 1;23(7):1017-26.

08/06/2006

Anti-TNF e rischio linfoma : una meta-analisi.....


28/05/2006

DDW 2006: efficacia e sicurezza dell'Adalimumab nella terapia del Crohn

Adalimumab Induces and Maintains Clinical Response and Remission in Patients With Active Crohn’s Disease: Results of the CHARM Trial J. Colombel; W. J. Sandborn; P. Rutgeerts; R. Enns; S. B. Hanauer; P. Remo; S. Schreiber; K. G. Lomax; P. F. Pollack

22/05/2006

I livelli dei metaboliti predicono la tossicità da tiopurine nelle IBD


19/05/2006

Lo stress non è un trigger per il relapse delle IBD


23/04/2006

Una nuova terapia per il Crohn?


18/04/2006

La prognosi del K colon in pazienti con IBD.......


14/04/2006

RCU Atto 1° e 2°: L'ora dell'Infliximab.


07/04/2006

Infliximab e rischio di neoplasia: uno studio multicentrico.......

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Gut. 2006 Feb;55(2):228-33. Epub 2005 Aug 24.

30/03/2006

Il fontolizumab (anti-interferon-gamma) nella terapia del Crohn


28/03/2006

USO DI STEROIDI, IMMUNOMODULATORI E INFLIXIMAB NELLE IBD


25/03/2006

I coxibs sono sicuri nella RCU.......


24/03/2006

E' possibile reintrodurre l'azatioprina in soggetti intolleranti?

Re-introduction of azathioprine in previously intolerant patients. Green CJ, Mee AS. Eur J Gastroenterol Hepatol. 2006 Jan;18(1):17-9

13/03/2006

Infliximab + metotrexate nella malattia di Crohn refrattaria


12/03/2006

Azatioprina vs 5-ASA nel trattamento della colite ulcerosa: un RCT !


14/02/2006

Fattori ambientali e IBD: uno studio di coorte…

Environmental Factors in Inflammatory Bowel Disease: A Co-Twin ControlStudy of a Swedish-Danish Twin Population.Halfvarson J, Jess T, Magnuson A, MontgomerySM, Orholm M, Tysk C, Binder V, Jarnerot G. Inflamm Bowel Dis. 2006 Oct;12(10):925-933.

14/02/2006

C'è un ruolo per il Natalizumab nella terapia del Crohn?

Natalizumab induction and maintenance therapy for Crohn's disease. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. N Engl J Med. 2005 Nov 3;353(18):1912-25.

13/02/2006

Trombofilia e IBD: una review….

Inflammation andCoagulation in Inflammatory Bowel Disease: The Clot Thickens.Danese S, Papa A, Saibeni S, Repici A, Malesci A,Vecchi M.Am J Gastroenterol.2006 Nov 13; [Epub ahead of print]

13/02/2006

Trombofilia e IBD: una review….

Inflammation andCoagulation in Inflammatory Bowel Disease: The Clot Thickens.Danese S, Papa A, Saibeni S, Repici A, Malesci A,Vecchi M.Am J Gastroenterol.2006 Nov 13; [Epub ahead of print]

12/02/2006

Crohn e rischio di cancro: una meta-analisi di studi osservazionali!


10/02/2006

Management della RCU sinistra e della proctite

Guidelines for the Medical Management of Left-Sided Ulcerative Colitisand Ulcerative Proctitis: Summary Statement.CHAR(13) + CHAR(10)Regueiro M, Loftus EV Jr, SteinhartAH, Cohen RD.CHAR(13) + CHAR(10)Inflamm Bowel Dis. 2006 Oct;12(10):972-978.

10/02/2006

Management della RCU sinistra e della proctite

Guidelines for the Medical Management of Left-Sided Ulcerative Colitisand Ulcerative Proctitis: Summary Statement.CHAR(13) + CHAR(10)Regueiro M, Loftus EV Jr, SteinhartAH, Cohen RD.CHAR(13) + CHAR(10)Inflamm Bowel Dis. 2006 Oct;12(10):972-978.

09/02/2006

RCU: la mesalazina MMX è sicura ed efficace

Once daily MMX mesalazine for the treatment ofmild-to-moderate ulcerative colitis: a phase II, dose-ranging study.D'Haens G, Hommes D, Engels L, Baert F, VAN DER WaaijL, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R. AlimentPharmacol Ther. 2006 Oct 1;24(7):1087-97.

07/02/2006

Review sulle IBD


27/01/2006

Tacrolimus nelle IBD ... una review

The Role of Tacrolimus in Inflammatory Bowel Disease: A SystematicReview.Gonzalez-Lama Y, Gisbert JP, Mate J.Dig Dis Sci. 2006 Sep 9; [Epubahead of print]

11/01/2006

IBD: infezione da CMV un riscontro frequente....

Frequent Detection of Cytomegalovirus in the Intestine of Patients withInflammatory Bowel Disease.Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Inflamm Bowel Dis. 2006 Sep;12(9):879-884.

08/01/2006

Azatioprina e rischio di linfoma


04/01/2006

Strategie di terapia nel m. di Crohn: step-up o top-down ?

V.Annese Scrive"Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down TherapyCHAR(13) + CHAR(10)Hommes D, Baert F, van Assche G, Caenepeel F, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Rutgeerts P, Feagan B, D’Haens GGastroenterology 2005,129:371CHAR(13) + CHAR(10)